Quest Diagnostics Elects Directors at Annual Meeting

The latest announcement is out from Quest Diagnostics ( (DGX) ).

At the 2025 Annual Meeting of Stockholders held on May 15, 2025, Quest Diagnostics announced the election of several directors for terms expiring at the 2026 Annual Meeting. The meeting also saw the approval of executive officer compensation and the ratification of PricewaterhouseCoopers as the independent registered public accounting firm for 2025. However, a stockholder proposal regarding calling a special meeting of stockholders was not approved.

The most recent analyst rating on (DGX) stock is a Buy with a $177.00 price target. To see the full list of analyst forecasts on Quest Diagnostics stock, see the DGX Stock Forecast page.

Spark’s Take on DGX Stock

According to Spark, TipRanks’ AI Analyst, DGX is a Outperform.

Quest Diagnostics is performing well with strong financials and a positive earnings outlook. Solid revenue growth and strategic partnerships enhance its position, though valuation is moderate. Technical indicators suggest a stable trend, and the reaffirmed guidance from the earnings call supports a positive future outlook. High debt levels and short-term technical weaknesses are areas to watch.

To see Spark’s full report on DGX stock, click here.

More about Quest Diagnostics

Quest Diagnostics is a leading company in the healthcare industry, primarily offering diagnostic testing services. The company focuses on providing insights into health and medical conditions, serving a wide range of stakeholders including patients, healthcare providers, and insurers.

Average Trading Volume: 1,377,606

Technical Sentiment Signal: Buy

Current Market Cap: $19.9B

Learn more about DGX stock on TipRanks’ Stock Analysis page.